I
Type I interferons (IFNs-a/b) are members of a heteroge-NTERLEUKIN-6 (IL-6) is a pleiotropic cytokine produced by a variety of cell types. 1 The various activities neous family of cytokines that activate some of the same of IL-6 are the result of its interaction with a membrane signaling intermediaries as IL-6. This is best documented in receptor consisting of an 80-kD ligand-binding a subunit the case of the Jak/STAT pathway. [33] [34] [35] The recent demon-(gp80), which triggers association with a 130-kD b subunit stration that IFN-b activates Erk2 and its association with (gp130), a common signaling component shared with other Stat1a has shown further similarities between the signaling members of the IL-6 cytokine superfamily.
2-4 Ligation of cascades triggered by IL-6 and IFNs-a/b, while providing a the IL-6 receptor induces homodimerization and tyrosine link between the ERK and Jak/STAT pathways. 36 Despite phosphorylation of gp130, and activation of associated memthe sharing of signaling components, type I IFNs, which bers of the Janus (Jak) family of protein tyrosine kinases. [5] [6] [7] [8] [9] bind competitively to a common receptor, [37] [38] [39] often induce The spectrum of Jak kinases activated is variable and reportthe opposite biologic effect in myeloma cells to that elicited edly cell-type specific. 6, 7 Formation of this signaling comby IL-6 (ie, growth arrest). [40] [41] [42] The mechanism through plex subsequently leads to the activation of two members which IFNs-a/b establish an antiproliferative state is largely (Stat1a and Stat3) of the STAT (signal transducer and activaunknown. Treatment with IFNs-a/b results in the induction tor of transcription) family of latent cytoplasmic transcripof a set of genes, including 2-5 oligoadenylate synthetase tion factors, 5,7,10-12 as specified by modular tyrosine-based and the double-stranded RNA-dependent protein kinase, motifs present in gp130. 13 Besides the Jak/STAT pathway, which may play a role in this process. 43 Transcription factors the extracellular signal-regulated kinase (ERK)/mitogensuch as the STATs and IRF-1 are involved in regulating the activated protein (MAP) kinase pathway has also been impliexpression of type I IFN-inducible genes. 35, 44, 45 cated as a signaling cascade mediating the various IL-6-It was previously reported that pretreatment of monocytes induced cellular responses. 4, [14] [15] [16] [17] [18] [19] with IFNg-g blocked colony-stimulating factor-1 (CSF-1)-One of the many biological activities of IL-6 is as a growth induced proliferation. 46 While CSF-1 receptor tyrosine phosfactor for murine plasmacytoma/hybridomas and human myphorylation and interaction with proximal signaling moleeloma cells. [20] [21] [22] [23] [24] Proteins potentially involved in transmission cules such as Grb2 were not affected, CSF-1-stimulated of a proliferative signal in these cells include components activation of Erk1/Erk2 was interrupted by IFNg-g treatof the Jak/STAT pathway, 6, 7, 19 as well as other nonreceptor ment, with protein kinase C (PKC)-d being identified as a tyrosine kinases 25 and as yet unidentified tyrosine-phosphorprimary target for the IFN-g-mediated inhibitory effects. In ylated proteins. 7, 26 However, activation by IL-6 of Raf-1, MEK1 (MAP kinase kinase) and Erk2 in myeloma cells implicates the ERK pathway, 18, 19 and two lines of indirect to the guanosine 5-triphosphate (GTP) form via the guanine 7.5), 137 mmol/L NaCl, 100 mmol/L NaF, 10% glycerol, 1% Nonithis study, we employed the human myeloma cell line U266 det P-40, 1 mmol/L Na 3 VO 4 , 1 mmol/L phenylmethylsulfonyl fluoto likewise investigate the mechanism of IFN-b-induced ride, 10 mg/mL aprotinin and 10 mg/mL leupeptin. Lysates were inhibition of IL-6-dependent cell growth.
incubated on ice for 15 minutes and particulate material removed by centrifugation for 10 minutes at 14,000g.
MATERIALS AND METHODS
For analysis of global patterns of protein tyrosine phosphorylation, 7 an equivalent volume of 2 1 SDS sample buffer (120 mmol/ Reagents. Recombinant human IL-6 (specific activity, 9.1 1 10 7 L Tris [pH 6.8], 4% SDS, 20% glycerol, and 100 mmol/L dithiothrei-U/mg) was a gift from Sandoz Pharmaceuticals Corp (East Hanover, tol) was added to the lysate, the samples were placed in a boiling NJ) and IFN-b (specific activity, 2.0 1 10 8 U/mg) was purchased water bath for 2 minutes, separated in SDS-polyacrylamide gels from Life Technologies, Inc (Gaithersburg, MD). The antiphosphoand transferred to Immobilon-P using 25 mmol/L Tris, 192 mmol/ tyrosine (anti-pTyr) monoclonal antibody (MoAb), 4G10, as well as L glycine, and 20% methanol. For immunoprecipitations, the lysate rabbit polyclonal antibodies to gp130, Jak1, Jak2, Tyk2, and Shc was precleared with protein A-sepharose (Pharmacia Biotech Inc) were purchased from Upstate Biotechnology, Inc (Lake Placid, NY).
for 1 hour followed by incubation with polyclonal antibodies for 1 The anti-pan-Erk and anti-PTP1D/Syp MoAbs were from Transducto 2 hours at 4ЊC, before collection of immune complexes with tion Laboratories (Lexington, KY) and the anti-Grb2 MoAb from protein A-sepharose for an additional 1 hour. The protein A-sephaSanta Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxirose beads were washed three times with lysis buffer, bound proteins dase-conjugated secondary antibodies were from Jackson Immunowere eluted by boiling in SDS-sample buffer, separated in SDSResearch Laboratories, Inc (West Grove, PA). Enhanced chemilumipolyacrylamide gels and transferred to Immobilon-P as described nescence reagents for Western blotting were purchased from above. Membranes were blocked with Tris-buffered saline conAmersham Canada Ltd (Oakville, Ontario) and Immobilon-P was taining 0.1% Tween-20 (TBS-T) and 6% bovine serum albumin for from Millipore Corp (Bedford, MA).
at least 1 hour, incubated with primary antibody for 1 hour, washed Cell culture. The human myeloma cell line U266, obtained from for 30 minutes with TBS-T, and developed with horseradish peroxithe American Type Culture Collection (Rockville, MD), was maindase-conjugated second antibody for 45 minutes. Blots were washed tained in Iscove's modified Dulbecco's medium (IMDM) suppleagain for 30 minutes with TBS-T, incubated with enhanced chemilumented with 50 mmol/L 2-mercaptoethanol and 10% heat inactivated minescence substrate solution and exposed to Kodak X-Omat film fetal calf serum (FCS; Life Technologies, Inc). For serum depriva-(Eastman Kodak, Rochester, NY). Immunoblots of immunoprecipition experiments, cells were grown in IMDM supplemented with tated Jak kinases were initially probed with 4G10, stripped by rinsing 0.5% FCS.
twice with 62.5 mmol/L Tris-HCl (pH 6.8), 2% SDS, 100 mmol/L Ras assay. The analysis of p21 ras -bound GTP/GDP was deter-2-mercaptoethanol for 20 minutes at 50ЊC, washed with TBS-T, and mined essentially as described previously. 47 Cells were collected, reprobed with either Jak1, Jak2, or Tyk2 as indicated. In the case washed twice with phosphate-free Dulbecco's modified Eagle's meof the Jak kinases, sequential immunoprecipitations were performed dium (ICN Pharmaceuticals, Montreal, Quebec, Canada) and resuson individual lysates. In these instances, lysates were cleared twice pended at a concentration of 2 1 10 6 cells/mL in the same medium with protein-A sepharose beads between successive immunoprecipicontaining 0.5% dialyzed FCS. After 12 hours, 0.2 mCi/mL of cartations to ensure that there was no carry over between experiments. rier-free 32 P i (Amersham) was added and the cells were incubated This was routinely confirmed by immunoblot analysis. for an additional 4 hours. When included, IFN-b (500 U/mL) was
In vitro binding studies. The glutathione S-transferase (GST) added 3 hours after the addition of 32 P i and 50 minutes before addiexpression constructs containing the Grb2 cDNA (GST-Grb2) or the tion of IL-6. Cells were more than 95% viable after deprivation as Grb2 SH2 domain (GST-Grb2SH2) have been previously dejudged by staining with trypan blue (0.04%). After activation with scribed. 48 GST-fusion proteins expressed in bacteria were prepared IL-6 (25 ng/mL) as indicated, cells were collected and washed twice by purification onto glutathione sepharose 4B beads (Pharmacia Biowith phosphate-buffered saline (PBS) containing 1 mmol/L sodium tech Inc, Piscataway, NJ) and used for binding assays as deorthovanadate (Na 3 VO 4 ), and lysed in 50 mmol/L HEPES (pH 7.4), scribed. 49, 50 For each reaction, lysates were precleared with glutathi-1% Triton X-100, 100 mmol/L NaCl, 5 mmol/L MgCl 2 , 1 mg/mL one sepharose 4B beads before incubation with GST-fusion proteins bovine serum albumin, 0.1 mmol/L phenylmethylsulfonyl fluoride, (5 to 10 mg) bound to these beads for 1 to 4 hours at 4ЊC. After 0.1 mmol/L GTP and 0.1 mmol/L guanosine 5-diphosphate (GDP).
incubation, the beads were collected and washed three times with Nuclei were removed by centrifugation and Ras protein was immulysis buffer. Protein complexes were then eluted in SDS-sample noprecipitated by the addition of 10 mg of rat anti-Ras MoAb (Y13-buffer and analyzed by Western blotting as described above. 259) for 1 hour at 4ЊC followed by the addition of protein G-Sepha- Plates were imaged and radioactivity quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) and the GTP/ RESULTS GTP/(1.5) GDP ratios calculated.
IFN-b inhibits [
3 H] thymidine incorporation in U266 cells. Changes in the tyrosine phosphorylation of Jak kinases following IFN-b pretreatment. Previously, we 7 and others 6, 19 showed that the protein tyrosine kinases Jak1, Jak2, the IL-6-induced protein tyrosine phosphorylation observed with IFN-b pretreatment were accompanied by altered phosphorylation of Jak kinases. As shown in Fig 4A , all three Jak effect on U266 growth. This inhibition of U266 proliferation kinases were rapidly (within 2.5 minutes) phosphorylated prompted us to examine the effects of IFN-b on IL-6-infollowing IL-6 stimulation of serum-starved U266 cells, duced signal transduction. Jak2, and Tyk2 being strongly phosphorylated and Jak1 less IFN-b blocks IL-6-induced protein tyrosine phosphorylaso. As expected, IFN-b selectively induced the phosphorylation. To determine if interruption of IL-6 signaling may tion of Jak1 and Tyk2, but had no effect on Jak2. Exposure account for the growth inhibitory effects of IFN-b, we invesof U266 cells to IL-6 following IFN-b pretreatment resulted tigated the changes in IL-6 signaling subsequent to IFN-b in further elevation in the levels of phosphorylation of Jak1 pretreatment. Analysis of serum-starved U266 myeloma and Tyk2. On the other hand, IFN-b pretreatment repressed cells stimulated with IL-6 showed the rapid induction of to some degree the IL-6-induced phosphorylation of Jak2, several tyrosine-phosphorylated proteins, the most promiraising the possibility that IFN-b might interfere with IL-6 nent of which have apparent molecular masses of 160, 145, signaling in U266 cells in part by attenuating Jak2 activation 87, 70, 52, 44 (weakly phosphorylated), and 42 kD (Fig 2A) .
(see Discussion). Concomitant with the decrease in Jak2 These tyrosine-phosphorylated proteins are similar in size phosphorylation was increased tyrosine phosphorylation of to a subset of those induced in ANBL-6 myeloma cells, 7 two coprecipitating proteins of higher apparent molecular suggesting their potential involvement in transmission of a mass. Reprobing of this blot with polyclonal antibodies mitogenic signal from IL-6. The induction kinetics varied against Jak2 showed no change in Jak2 protein levels followsomewhat among these proteins: p160, p70, and p52 demoning IFN-b treatment (Fig 4B) . strated peak phosphorylation by 2.5 minutes, which declined IFN-b pretreatment influences the activation of p21 ras by thereafter, while p87, p44, and p42 showed a progressive IL-6. Because p21 ras involvement in IL-6-induced activaincrease in phosphorylation for at least 5 minutes. In all tion of Erk2 in the AF10 subclone of U266 cells had been cases, the levels of phosphorylation declined to basal states inferred, 18, 19 we next decided to examine directly the ability by 30 minutes. The 70-, 52-, 44-, and 42-kD proteins have of IL-6 to induce GTP loading of p21 ras in our U266 cell line mobilities similar to PTP1D/Syp, p52 shc , Erk1 (p44 mapk ) and and to assess whether IFN-b affected this process. Although Erk2 (p42 mapk ), respectively. 19, 30, 49, 52, 53 The identity of these p21 ras has been implicated in IL-6-mediated signaling in proteins was confirmed by further studies (see below).
other systems, 4,29 there has been only one previous report Serum-starved U266 cells were next treated with various documenting an increase in GTP-bound p21 ras in IL-6-stimdoses of recombinant IFN-b 50 minutes before stimulation ulated cells. This involved the rat PC12 pheochromocytoma with IL-6 for 10 minutes (Fig 2B) . IFN-b pretreatment was cell line, which can be induced to differentiate into neuronfound to significantly inhibit the IL-6-induced tyrosine like cells by IL-6 55 ; in the PC12 system, p21 ras activation phosphorylation of p160, p145, p87, p70, and p42. In genwas apparent only if the cells were pretreated with sodium eral, the lowest IFN-b dose employed (125 U/mL) was suforthovanadate, a potent inhibitor of phosphotyrosine phosficient to accomplish maximal inhibition. The identity of p42 phatases, but which possesses other pharmacological activias Erk2 was confirmed in a similar experiment (Fig 2C) . ILties. 14 Accordingly, we determined the activation state of 6 induced both tyrosine phosphorylation and a shift in the p21 ras in serum-starved U266 cells treated with IL-6 by labelmobility of Erk2 (denoted pErk2), which were inhibited by IFN-b pretreatment (500 U/mL ras following exposure to IL-6 was rapid with 19% of nucleotide bound by 2 minutes and decreasing (Ewing's sarcoma) cells with the IL-6-type cytokine ciliary neurotrophic factor, and Stahl et al 13 identified the tyrosineshortly thereafter (data not shown). When IFN-b was added before IL-6 treatment of U266 cells, a partial inhibition of based motif in gp130, which is required for binding of PTP1D/Syp. To determine the status of PTP1D/Syp phos-IL-6-stimulated p21 ras activation was observed, with the maximum percentage of GTP bound to p21 ras detected at 2 phorylation in this system, U266 cells, with or without IFNb pretreatment, were exposed to IL-6 and the degree of minutes reaching only 13%. These data thus established that p21 ras is a downstream component of an IL-6 signaling pathtyrosine phosphorylation of PTP1D/Syp was evaluated following immunoprecipitation with a PTP1D/Syp-specific way associated with cellular proliferation. 56 Moreover, the decreased GTP-loading of p21 ras observed after IFN-b treatMoAb. As shown in To further investigate the nature of the interaction between PTP1D/Syp and Grb2, we repeated the in vitro bead-binding assays using a GST-fusion protein containing the Grb2 Src homology 2 (SH2) domain. As can be seen in Fig 7C , the results were essentially identical to those obtained with the full-length Grb2 protein, establishing that the PTP1D/SypGrb2 complex formed upon IL-6 stimulation, and disrupted by IFN-b pretreatment, occurs through binding of the Grb2 SH2 domain to tyrosine-phosphorylated PTP1D/Syp. These data also indicate that a similar mechanism is operative for the IL-6-stimulated and IFN-b-inhibited interaction of Grb2 with p145. Finally, the data argue that the constitutive association of tyrosine-phosphorylated p85 is likewise mediated by the Grb2 SH2 domain and that the additional proteins that bind to the full-length GST-Grb2 fusion in lysates of IL-6-and/or IFN-b-treated U266 cells must interact with other regions of Grb2, as no proteins bound to GST alone ( Fig 7D) . the lower panel of Fig 6, IL-6 induced an association between these proteins, which was significantly impaired by IFN-b pretreatment.
We next examined the interaction of Grb2 with PTP1D/ Syp by performing Grb2 immunoprecipitations and Western blotting with anti-pTyr, anti-PTP1D/Syp, and anti-Grb2 MoAbs (Fig 7A) . A constitutively tyrosine-phosphorylated protein of 82 kD (p82) coprecipitated with Grb2 under all conditions. IL-6 stimulation induced the tyrosine phosphorylation of a protein in the anti-Grb2 immunoprecipitates, which was identified as PTP1D/Syp. Pretreatment with IFNb before IL-6 exposure was found to significantly reduce the amount of tyrosine-phosphorylated PTP1D/Syp that coprecipitated with Grb2.
To obtain data supporting the notion that IL-6-induced tyrosine phosphorylation of PTP1D/Syp enables formation of PTP1D/Syp-Grb2 complexes in this system and that IFNb pretreatment negatively influenced this association, we next performed in vitro bead-binding assays using GSTfusion proteins. In the first set of experiments, a GST-fusion MoAbs (Fig 7B) . The GST-Grb2 fusion protein bound an for 50 minutes and then exposed to IL-6 (25 ng/mL) for the times 82-kD tyrosine-phosphorylated protein in untreated lysates, 15, 48 has also been reported to associate with Grb2 after IL-6 stimulation. 19 We confirmed and extended these findings by probing the blots shown in Fig  7 with Shc-specific antibodies (Fig 8) . We were able to detect only the 52-kD isoform of Shc bound to the Grb2 GSTfusion proteins and found that IL-6 stimulated enhanced association of this protein with both full-length Grb2, as well as the SH2 domain of Grb2. IFN-b treatment itself resulted in increased association of p52
shc with Grb2 at the 50-minute time point, although the enhanced binding of p52 shc to Grb2 seen following IL-6 treatment was significantly hindered. We could not detect any binding of p46 shc to the Grb2 GSTfusion proteins even though this isoform was readily detected in whole cell lysates (see Fig 9) . These results were corroborated by Western blot analysis of anti-Shc immunoprecipitates with anti-Grb2 MoAbs (Fig 8) .
In addition to Grb2, Shc has also recently been shown to interact with tyrosine-phosphorylated proteins of approximately 145 kD (p145) in certain hematopoietic cell lines stimulated with IL-3, Steel factor, and erythropoietin, 60 ,61 as well as in fibroblasts stimulated with platelet-derived growth factor (PDGF) or fibroblast growth factor. 62 We had noted (Fig 2A) and shows sensitivity to (Fig 2B) . An IFN-sensitive tyrosinephosphorylated protein(s) in this size range was also found to associate with Grb2 in response to IL-6 (Fig 7B and C) . To determine whether Shc might be associated with a 145-kD tyrosine-phosphorylated protein in IL-6-stimulated U266 cells and whether IFN-b pretreatment might affect the tyrosine phosphorylation state of Shc and/or this interaction, cells with or without IFN-b pretreatment were incubated with IL-6 for various times, lysed, and subjected to immunoprecipitation with anti-Shc antibodies followed by immunoblotting with the anti-pTyr MoAb. As can be seen in Fig  9, the p52 shc and p46 shc isoforms of Shc were tyrosine phosphorylated at a basal level. Upon stimulation with IL-6, the levels of phosphorylation of both p52 shc and p46 shc increased and a 145-kD tyrosine-phosphorylated protein was present in the immunoprecipitates. Tyrosine phosphorylation of the 145-kD Shc-binding protein was maximal at 2.5 minutes. At (Fig 8) . (p45) was also found in the anti-Shc immunoprecipitates DISCUSSION following IFN-b treatment. When cells that had been preRecent studies have identified components of the canonitreated with IFN-b were subsequently exposed to IL-6, both cal Ras pathway as targets for growth inhibitory molecules. p145 and p45 coprecipitated with p52 shc and p46
IFN-b pretreatment
shc . Whereas For example, elevated cyclic adenosine 5-monophosphate the levels of tyrosine phosphorylation of both Shc isoforms levels have been reported to block growth factor-induced and p45 were slightly increased 2.5 minutes after exposure mitogenic signaling by interfering with ERK activation at to IL-6, the level of tyrosine phosphorylation of p145 (or the level of Raf-1. 63 More recently, it was shown that IFNthe amount of tyrosine-phosphorylated p145 bound to Shc) g blocked CSF-1-stimulated proliferation of monocytes 46 was reduced compared with that observed in response to ILalso by delivering an antiproliferative signal to the ERK pathway. In this case, PKC-d was identified as a potential 6 alone.
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It is tempting to speculate that this modulation of Jak2 activation may account for the reduced phosphorylation of gp130 because successive treatment with INF-b and IL-6 had an additive effect on Jak1 and Tyk2 tyrosine phosphorylation. However, reduced availability of the IFN-b used kinases; Jak1 and Tyk2, could also contribute to the level of IL-6-induced gp130 tyrosine phosphorylation. This scenario implies functional nonequivalency among the Jak/Tyk kinases, a characteristic recently described in human fibrosarcoma cells activated with IL-6 64 and IFN-b. 66 Overexpression of dominant-negative mutants of Jak kinases in U266 cells will be necessary to define the role of each kinase in these cells. 64, 66, 67 Abrogation of gp130 tyrosine phosphorylation would be predicted to block activation of SH2-containing signaling components, which function by directly interacting with the sites involved. Stahl et al 13 identified the gp130 tyrosine motifs essential for interaction with a number of SH2-con- cule leading to the downstream activation of p21 ras in PDGFstimulated fibroblasts and other cells.
58, 59 Tyrosine phosphorylation of the PDGFR is followed by SH2-mediated binding target for inhibition at a point upstream of Raf-1. In U266 myeloma cells, we have demonstrated partial downregulation of IL-6-induced Erk2 and p21 ras activation with the IFN-b pretreatment regimen employed. Using PKC inhibitors (staurosporin and calphostin C), we were unable to demonstrate a significant role of PKC in IL-6 signal transduction (data not shown). 26 In addition, pretreatment of U266 cells with IFN-b had no effect on the ability of phorbol 12-myristate 13-acetate to activate Erk2 in these cells (data not shown). Taken together, these results imply that PKC-d is probably not a target for IFN-b blockage of IL-6-stimulated U266 proliferation; the ERK/MAP kinase pathway activated by IL-6 in U266 cells thus differs qualitatively from that induced by CSF-1.
To identify the receptor proximal components responsible for the IFN-b-induced decrease in activation of p21 ras and Erk2, we investigated the effects of IFN-b on other IL-6 signaling molecules. The most upstream signaling component affected by IFN-b pretreatment was gp130, in which a partial downregulation of IL-6-induced tyrosine phosphorylation was detected. This finding, which most likely accounts for the subsequent disruption of downstream signaling events, distinguishes the present study from the IFN-g induced effects on CSF-1 signaling, 46 where no changes in receptor tyrosine phosphorylation were observed. The For personal use only. on October 3, 2017. by guest www.bloodjournal.org From of PTP1D/Syp, recruitment of Grb2-SOS, and subsequent will be important to determine the relationship of p145 observed here to this 5-phosphatase. If p145 does function as p21 ras activation. Results reported here indicate that a similar signaling pathway is activated by IL-6 in U266 cells. Morea potential regulator of p21 ras activity, it is plausible that the 45-kD tyrosine-phosphorylated protein that also coprecipiover, we have found that IL-6-stimulated PTP1D/Syp activation, as defined by tyrosine phosphorylation and interactated with Shc proteins following IFN-b treatment may act by preventing the formation of IL-6-induced Shc-p145 comtion with gp130 and Grb2, is significantly impaired by IFN-b strongly suggesting that this interruption leads to the plexes. In any event, these data implicate Shc as another potential point of convergence of the IL-6 and IFN-b signalobserved reduction in IL-6-induced p21 ras and Erk2 activation.
ing pathways in U266 cells. It was recently reported that IFN-b activates Erk2 in U266 Whether the catalytic activity of PTP1D/Syp mediates IL-6 signal transduction or functions by interrupting these sigcells, inducing its association with Stat1a. 36 We likewise observed activation of Erk2 following IFN-b challenge of naling events in response to IFN-b remains to be determined. Because Kumar et al 19 reported that IL-6 does not induce our U266 cells (unpublished results, June 1995). Notably, activation of Erk2 by IFN-b differs in both magnitude and tyrosine phosphorylation of any of the members of the Src family of protein tyrosine kinases expressed in a subclone kinetics compared with that elicited by IL-6, with IL-6 inducing a more rapid and greater increase in Erk2 tyrosine phosof U266 cells (AF10), it seems unlikely that dephosphorylation of the negatively regulating phosphotyrosine in these phorylation. IFN-b also modified other signaling molecules used by IL-6 including induction of gp130 tyrosine phosproteins would play any role. A more likely candidate substrate for PTP1D/Syp would be Jak2. Indeed Fuhrer et al 65 phorylation, interaction of PTP1D with gp130 and Grb2 and Grb2-Shc association. The role of these modifications in recently described a direct physical association between Jak2 and PTP1D/Syp in IL-11-treated preadipocytes. We pre-IFN-b signaling and their contribution to IL-6/IFN-b crosstalk is currently under investigation. viously demonstrated that IL-6 and IL-11 induce common signaling molecules in murine plasmacytomas and hybridIn summary, the results presented here support a model in which IFN-b modifies the Ras-dependent ERK/MAP kinase omas, 7 making a physical association between Jak2 and PTP1D/Syp a reasonable possibility in IL-6-stimulated hupathway of IL-6 signaling in U266 cells. We propose that this occurs through the disruption of gp130-PTP1D/Sypman myeloma cells. Additional support for this type of mechanism comes from the finding that the related SH2
Grb2 and Grb2-Shc complexes. The partial inhibition of IL-6-induced tyrosine phosphorylation of Jak2 by IFN-b domain-containing phosphotyrosine phosphatase PTP1C (also referred to as SHPTP1, HCP, and SHP) negatively suggests that this kinase may be a primary target for the antagonistic IFN-b signaling effects. In this manner, IFN-b regulates IFN signaling through dephosphorylation of Jak1.
68
Besides PTP1D/Syp, Grb2 binds to additional tyrosinepretreatment downregulates IL-6-stimulated Jak2 phosphorylation of gp130 at sites necessary for association of PTP1D/ phosphorylated proteins present in lysates from IL-6-induced U266 cells, including one or more proteins with moSyp. The reduced phosphorylation of Jak2 may result from IFN-b-induced activation of a Jak2-specific phosphotyrolecular mass of approximately 145 kD. The significance of this binding is unknown at present, as we did not observe sine phosphatase, with PTP1D/Syp itself being a candidate, or it may represent competition between Jak1/Tyk2 and Jak2 this association in vivo (ie, in Grb2 immunoprecipitations). A potential explanation for this discrepancy could be that for gp130. 64 there is a hierarchy of protein-protein interactions, which is not maintained under conditions of excess GST-Grb2 in NOTE ADDED IN PROOF vitro. Alternatively, the bacterially expressed GST-Grb2 Recently, Chin et al (Science 272:719, 1996) identified may not faithfully mimic the endogenous protein.
the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 as a priAnother protein known to function upstream of p21 ras in mary target for IFN-g-mediated cell growth suppression by several systems is the adaptor protein Shc. 15, 48 We have con-STAT proteins. firmed a prior report that IL-6 induces tyrosine phosphorylation of p52 shc and its association with Grb2 in myeloma ACKNOWLEDGMENT cells. 19 We also found that IL-6 stimulates tyrosine phosphor- 
